Devaurs, D. et al. (2018) “Native State of Complement Protein C3d Analysed via Hydrogen Exchange and Conformational Sampling”, International journal of computational biology and drug design, 11(1-2), pp. 90–113. Available at: 10.1504/ijcbdd.2018.090834.   edoc

Primikyri, A. et al. (2017) “Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS”, Journal of Chromatography B, 1041-1042, pp. 19–26. Available at: 10.1016/j.jchromb.2016.12.004.   edoc

Devaurs, D. et al. (2017) “Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data”, Frontiers in Molecular Biosciences, 4, p. 13. Available at: 10.3389/fmolb.2017.00013.   edoc

Harder, M.J. et al. (2017) “Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation”, Blood, 129(8), pp. 970–980. Available at: 10.1182/blood-2016-08-732800.   edoc

Mastellos, D.C. et al. (2017) “Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery”, Trends in Immunology, 38(6), pp. 383–394. Available at: 10.1016/j.it.2017.03.003.   edoc

Yuan, X. et al. (2017) “Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy”, Cancer Immunology, Immunotherapy, 66(3), pp. 367–378. Available at: 10.1007/s00262-016-1937-z.   edoc

Papanastasiou, M. et al. (2017) “Structural Implications for the Formation and Function of the Complement Effector Protein iC3b”, Journal of immunology (Baltimore, Md. : 1950), 198(8), pp. 3326–3335. Available at: 10.4049/jimmunol.1601864.   edoc

Xue, X. et al. (2017) “Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses”, Nature Structural and Molecular Biology, 24(8), pp. 643–651. Available at: 10.1038/nsmb.3427.   edoc

Blatt, A.Z. et al. (2017) “Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation”, Frontiers in Immunology, 8, p. 1586. Available at: 10.3389/fimmu.2017.01586.   edoc | Open Access

Wang, H., Ricklin, D., Lambris, J.D. (2017) “Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4”, Proceedings of the National Academy of Sciences of the United States of America, 114(41), pp. 10948–10953. Available at: 10.1073/pnas.1707364114.   edoc

Ricklin, D., Barratt-Due, A., Mollnes, T.E. (2017) “Complement in clinical medicine: Clinical trials, case reports and therapy monitoring”, Molecular Immunology, 89, pp. 10–21. Available at: 10.1016/j.molimm.2017.05.013.   edoc | Open Access

Hajishengallis, G. et al. (2017) “Novel mechanisms and functions of complement”, Nature Immunology, 18(12), pp. 1288–1298. Available at: 10.1038/ni.3858.   edoc

Lindorfer, M.A. et al. (2016) “Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia”, Clinical Immunology, 171, pp. 32–35. Available at: 10.1016/j.clim.2016.08.017.   

Mastellos, D.C. et al. (2016) “From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage”, Immunobiology, 221(10), pp. 1046–1057. Available at: 10.1016/j.imbio.2016.06.013.   

Ricklin, D., Reis, E.S., Lambris, J.D. (2016) “Complement in disease: a defence system turning offensive”, Nature Reviews Nephrology, 12(7), pp. 383–401. Available at: 10.1038/nrneph.2016.70.   

Blatt, A.Z. et al. (2016) “Properdin-mediated c5a production enhances stable binding of platelets to granulocytes in human whole blood”, Journal of Immunology, 196(11), pp. 4671–4680. Available at: 10.4049/jimmunol.1600040.   

Hajishengallis, G. et al. (2016) “Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application”, Seminars in Immunology, 28(3), pp. 285–291. Available at: 10.1016/j.smim.2016.03.006.   

Ricklin, D., Lambris, J.D. (2016) “Complement therapeutics”, Seminars in Immunology, 28(3), pp. 205–207. Available at: 10.1016/j.smim.2016.07.001.   

Ricklin, D., Lambris, J.D. (2016) “Therapeutic control of complement activation at the level of the central component C3”, Immunobiology, 221(6), pp. 740–746. Available at: 10.1016/j.imbio.2015.06.012.   

Ricklin, D., Lambris, J.D. (2016) “New milestones ahead in complement-targeted therapy”, Seminars in Immunology, 28(3), pp. 208–222. Available at: 10.1016/j.smim.2016.06.001.   

Forneris, F. et al. (2016) “Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode”, EMBO Journal, 35(10), pp. 1133–1149. Available at: 10.15252/embj.201593673.   

Schmidt, C.Q. et al. (2016) “Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients”, Immunobiology, 221(4), pp. 503–511. Available at: 10.1016/j.imbio.2015.12.009.   

Maekawa, T. et al. (2016) “Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3”, Journal of Clinical Periodontology, 43(3), pp. 238–249. Available at: 10.1111/jcpe.12507.   

Mastellos, D. et al. (2016) “Complement therapeutics in inflammatory diseases: Promising drug candidates for C3-targeted intervention”, Molecular Oral Microbiology, 31(1), pp. 3–17. Available at: 10.1111/omi.12129.   

Harder, M.J. et al. (2016) “Comparative analysis of novel complement-targeted inhibitors, MiniFH, and the natural regulators factor H and factor H-like protein 1 reveal functional determinants of complement regulation”, Journal of Immunology, 196(2), pp. 866–876. Available at: 10.4049/jimmunol.1501919.   

Ricklin, D., Lambris, J.D. (2016) “Preformed mediators of defense-Gatekeepers enter the spotlight”, Immunological Reviews, 274(1), pp. 5–8. Available at: 10.1111/imr.12497.   edoc

Ricklin, D. et al. (2016) “Complement component C3 - The ‘Swiss Army Knife’ of innate immunity and host defense”, Immunological Reviews, 274(1), pp. 33–58. Available at: 10.1111/imr.12500.   edoc

Schmidt, C.Q., Lambris, J.D., Ricklin, D. (2016) “Protection of host cells by complement regulators”, Immunological Reviews, 274(1), pp. 152–171. Available at: 10.1111/imr.12475.   edoc

Wang, J. et al. (2016) “Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40”, Clinical Immunology, 162, pp. 37–44. Available at: 10.1016/j.clim.2015.11.002.   

Reis, E.S. et al. (2015) “Applying complement therapeutics to rare diseases”, Clinical Immunology, 161(2), pp. 225–240. Available at: 10.1016/j.clim.2015.08.009.   

Georgoutsou-Spyridonos, M. et al. (2015) “Attenuation of Staphylococcus aureus-induced bacteremia by human mini-antibodies targeting the complement inhibitory protein Efb”, Journal of Immunology, 195(8), pp. 3946–3958. Available at: 10.4049/jimmunol.1500966.   

Lin, Z. et al. (2015) “Complement C3dg-mediated erythrophagocytosis: Implications for paroxysmal nocturnal hemoglobinuria”, Blood, 126(7), pp. 891–894. Available at: 10.1182/blood-2015-02-625871.   

Zhang, Y. et al. (2015) “Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy”, Immunobiology, 220(8), pp. 993–998. Available at: 10.1016/j.imbio.2015.04.001.   

Reis, E.S. et al. (2015) “Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters”, Immunobiology, 220(4), pp. 476–482. Available at: 10.1016/j.imbio.2014.10.026.   

Mastellos, D.C. et al. (2015) “Compstatin: A C3-targeted complement inhibitor reaching its prime for bedside intervention”, European Journal of Clinical Investigation, 45(4), pp. 423–440. Available at: 10.1111/eci.12419.   

Sfyroera, G. et al. (2015) “Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity”, Journal of Immunology, 194(7), pp. 3305–3316. Available at: 10.4049/jimmunol.1402781.   

Rafail, S. et al. (2015) “Complement deficiency promotes cutaneous wound healing in mice”, Journal of Immunology, 194(3), pp. 1285–1291. Available at: 10.4049/jimmunol.1402354.   

Kourtzelis, I. et al. (2015) “Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium”, Hormone and Metabolic Research, 47(1), pp. 36–42. Available at: 10.1055/s-0034-1390452.   

Hamad, O.A. et al. (2015) “Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18”, Thrombosis and Haemostasis, 114(6), pp. 1207–1217. Available at: 10.1160/TH15-02-0162.   

Woehl, J.L. et al. (2014) “The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase”, Journal of Immunology, 193(12), pp. 6161–6171. Available at: 10.4049/jimmunol.1401600.